UPDATE 12/23/2020: Judge Blake of the US District Court for the District of Maryland has granted a temporary restraining order on the Most Favored Nation rule.
Top pharmaceutical organizations...
Specialty drugs accounted for 37.7 percent of retail and mail order prescription spending net of rebates in 2016-2017, a recent Health Affairs study found.
Researchers leveraged nationally...
The Department of Justice (DOJ) recently announced an $8.3 billion settlement in which opioid manufacturer, Purdue Pharmaceuticals, agreed to plead guilty to a three-count felony.
As part of the...
The worldwide pharmaceutical market was worth approximately $1.3 trillion in 2019, with the top ten pharmaceutical companies accounting for nearly a third of sales, according to a market research...
A recent analysis found that product hopping for just five brand-name drugs costs the US healthcare system $4.7 billion annually.
The analysis from Matrix Global Advisors examined the effects...
A recent study found that switching from brand name to generic cholesterol medications has saved Medicare billions of dollars between 2014 and 2018, even as the number people on cholesterol-lowering...
A study recently published in JAMA Network Open found that nearly one-third of sole-source, off-patent, and off-exclusivity drug products saw major increases in drug prices over any calendar year.
In...
A coalition of 28 states and territories recently sued Mallinckrodt ARD LLC over accusations that the pharmaceutical company violated the False Claims Act and knowingly underpaid Medicaid drug rebates...
In states that switched to drug reimbursement models where results were based on a survey of pharmacy invoices, researchers found no effect on overall Medicaid outpatient drug spending, according to a...
The German Pharmaceutical Market Restructuring Act (AMNOG) is an example of how a drug pricing strategy can be designed to better align prices with clinical benefit and is an approach the US can take...
The Institute for Clinical and Economic Review (ICER) suggested that Gilead Sciences antiviral remdesivir could be priced up to $5,080 per course based on benefits shown in COVID-19 patients, according...
Medicaid spent an estimated $761 million in excess costs over seven years due to delayed generic drug entry costs, according to a recent study.
Delayed generic drug entry is common,...
US taxpayers and the healthcare sector may save nearly $7 billion annually with a stronger, more competitive biosimilars market, which is a significant increase from the current annual cost-savings of...
The Department of Justice announced that Apotex Corp, a generic pharmaceutical company, agreed to pay a $24.1 million criminal penalty for the role it played in antitrust violations from May 2013 to...
Two-thirds of US adults reported that prescription drug prices have increased either “a little” or “a lot” since 2017, the first year of the Trump administration, according to a...
Repurposed generics show promise as potential COVID-19 drugs and may be manufactured profitably at very low costs, according to a recent study.
For more coronavirus updates, visit...
Eli Lilly and Company recently launched a program allowing anyone with or without commercial insurance to fill their monthly prescription of Lilly insulin for $35, boosting patient access to insulin...
When matched for all characteristics, two biosimilars showed significant cost savings for large US employers, according to researchers from the Bloomberg School of Public Health at Johns Hopkins...
Patients will now have access to a cheaper version of the drug at the center of a recent price gouging case. In an announcement on Feb. 28, the FDA reported that it has approved the first generic drug...
Two members of the United States Committee on Finance made a final document request to pharmacy benefit manager Express Scripts, owned by Cigna, and warned that failure to comply will result in a...
